Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double- Blind, Placebo Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

NCT01626573 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT01626573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01626573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double- Blind, Placebo Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2012
Completion date
October 31, 2013
Enrollment
106 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis